Lumos Diagnostics Holdings Ltd
OTC:LDXHF
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
194.6m AUD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.3T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.3B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.4B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
121.7B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
11.6B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.9B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.9B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.1B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.2T KRW |
Loading...
|
Market Distribution
| Min | -14 949 200% |
| 30th Percentile | -526.4% |
| Median | -25.2% |
| 70th Percentile | 6.1% |
| Max | 145 596.9% |
Other Profitability Ratios
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Lumos Diagnostics Holdings Ltd is -50.2%, which is above its 3-year median of -66.7%.
Over the last 3 years, Lumos Diagnostics Holdings Ltd’s Operating Margin has increased from -202.9% to -50.2%. During this period, it reached a low of -202.9% on May 30, 2022 and a high of -30.1% on Dec 31, 2024.
